Multiple sclerosis (MS) is a complex disease of the CNS that usually affects young adults, although 3-5% of cases are diagnosed in childhood and adolescence (hence called pediatric MS, PedMS). Genetic predisposition, among other factors, seems to contribute to the risk of the onset, in pediatric as in adult ages, but few studies have investigated the genetic 'environmentally naïve' load of PedMS. The main goal of this study was to identify circulating markers (miRNAs), target genes (mRNAs) and functional pathways associated with PedMS; we also verified the impact of miRNAs on clinical features, i.e. disability and cognitive performances. The investigation was performed in 19 PedMS and 20 pediatric controls (PCs) using a HighThroughput Next-generation Sequencing (HT-NGS) approach followed by an integrated bioinformatics/biostatistics analysis. Twelve miRNAs were significantly upregulated (let-7a-5p, let-7b-5p, miR-25-3p, miR-125a-5p, miR-942-5p, miR-221-3p, miR-652-3p, miR-182-5p, miR-185-5p, miR-181a-5p, miR-320a, miR-99b-5p) and 1 miRNA was downregulated (miR-148b-3p) in PedMS compared with PCs. The interactions between the significant miRNAs and their targets uncovered predicted genes (i.e. TNFSF13B, TLR2, BACH2, KLF4) related to immunological functions, as well as genes involved in autophagy-related processes (i.e. ATG16L1, SORT1, LAMP2) and ATPase activity (i.e. ABCA1, GPX3). No significant molecular profiles were associated with any PedMS demographic/clinical features. Both miRNAs and mRNA expressions predicted the phenotypes (PedMS-PC) with an accuracy of 92% and 91%, respectively. In our view, this original strategy of contemporary miRNA/mRNA analysis may help to shed light in the genetic background of the disease, suggesting further molecular investigations in novel pathogenic mechanisms.
Introduction
Multiple sclerosis (MS) is a complex multifactorial disease of the CNS characterized by inflammatory autoimmune demyelination and neurodegeneration (1) . Usually identified as a disease of young adults, improvements in diagnostic tools and/or an increased sensitivity to its first signs and symptoms may have also contributed to a better recognition of MS during the very early ages of life, whereas in the past it had been mostly retrospectively tracked. At present, pediatric MS (PedMS) represents 3-5% of all MS cases; Relapsing Remitting MS (RRMS) is considered the most frequent form of the disease, with a relapse rate higher than the adult RRMS, in line with the evidence of more pronounced inflammatory MRI features (2) (3) (4) (5) .
Genetic predisposition, lifestyle, and environmental factors seem to contribute significantly to the overall risk of the onset of MS (6) . Since the rarity of PedMS occurrence, and considering the general assumption that pediatric and adult MS patients should share the same risk factors (7) , very few studies have investigated the genetic involvement of PedMS. However, children with MS can be considered 'environmentally naïve' so their genetic load may provide more significant information than in adult patients, especially about those genetic factors that trigger the onset of the disease at younger ages (8) or modulate its phenotypes. Identifying these peculiarities would be of valuable help, for example, in the search of more targeted therapeutic approaches.
Indeed, recent studies demonstrated that a genetic architecture of the normal human developing brain does exist, mostly driven by a given set of microRNAs (miRNAs) acting as agerelated transcription factors on genes enclosed in specialized functional networks (9) . miRNAs are a class of non-coding RNA (ncRNA) genes whose products are small single-strand RNAs (with lengths of about 22 nucleotides) involved in the regulation of translation of over 60% mammalian genes (10, 11) . Deregulation of miRNAs expression may be involved in a broad spectrum of cellular and biological processes including apoptosis and cell proliferation, and it has been also observed in molecular dysfunctions underlying several neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) (12), Parkinson's Disease (PD) (13) , and Dementias (14) .
In MS, it has been reported that miRNAs are not only involved in the pathogenesis of the disease (15) but also associated with different MS subtypes (16, 17) , as well as with the response to specific treatments like Interferon Beta-1b (18) , Natalizumab (19) , or Glutiramer Acetate (20) , thus confirming their potential as biomarkers of disease monitoring. So far, no miRNAs investigations have been performed in PedMS.
The main goal of this study was to identify patterns of circulating markers (miRNAs) associated with a selected population of PedMS submitted to periodical clinical examinations and compared with a pediatric control population of healthy subjects (PCs). By using a High-Throughput Next-generation Sequencing (HT-NGS) approach, we were able to characterize different miRNAs and their target genes, and analysed the output data in house by an integrated team of bioinformatics and biostatistics personnel with long-standing expertise in NGS data analysis (Fig. 1) , in order to uncover molecular pathway/s associated with PedMS. Additional aim was to search for transcriptomic profiles (miRNAs/mRNAs) distinctive of PedMS features, such as clinical disabilities or cognitive dysfunctions.
Results
The study population consisted of 19 patients with PedMS and 20 PCs (Table 1) ; they differed significantly for age at the study entry (P ¼ 0.001), whereas no significant gender difference was found between them (P > 0.05) (Please also visit: http://www.ba. itb.cnr.it/pedms/ for graphical and data support).
PedMS patients were analysed during the inactive phase of a RR course of the disease (no clinical relapses or steroid assumption within 30 days of the study entry, no Gd-enhancing lesions at the concomitant MRI) and were steroid-free (at least one month prior to the blood sample). Ten out of the 19 patients had never assumed disease-modifying treatment (DMT) at the time of the blood test, whereas the remaining 9 had taken Interferon Beta-1a for a range of 21-673 days from the blood samples. Seventeen PedMS patients completed the neuropsychiatric evaluation; 7 of them (41%) tested cognitively impaired (CI). No significant differences were found between CI_PedMS and the cognitively preserved ones (CP) for gender, age at MS onset, diseases duration, EDSS and years of education (P > 0.05).
Analysis of miRNAs and mRNAs differentially expressed (DE)
The bioinformatics analysis of HT-NGS data produced the following results. The comparisons of miRNAs expression levels within the study groups revealed 49 mature miRNAs significantly DE between PedMS and PCs (40 up-regulated and 9 downregulated) (Supplementary Material). No miRNAs discriminated CI-PedMS from CP-PedMS subjects.
After further selection (miRNAs with mean number of reads > 25, Fold Change > 1.5 and Dispersion Index range 0-1.6), we restricted the total list to 27 miRNAs that were subjected to qRT-PCR technical validation ( Table 2) .
The contemporary comparative analysis of mRNA-seq reads identified 4,306 genes significantly DE between PedMS and PCs (2215 upregulated and 2091 downregulated). No significantly DE miRNAs/genes resulted associated with any clinical features or DMT treatment in PedMS (data available not showed).
Prediction accuracy of DE analysis
The differences at molecular levels, highlighted by the DE analyses in which the transcripts were analysed singularly, were confirmed by a global analysis. In particular, the differences between two phenotypic conditions were analysed by comparing the whole profile of the subjects using the prediction accuracy (ACC) method. The higher the ACC value, the stronger the difference at the molecular level between the two phenotypic conditions analysed. Patients with PedMS showed deeply altered miRNA and mRNA expressions when compared with PCs subjects, since we were able to predict the phenotypic status of a subject with ACC values of 92% and 91%, respectively, using only their expression profiles.
qRT-PCR technical validation (miRNAs)
Five candidate endogenous reference genes (miR-93-5p, miR103a-3p, miR-106b-5p, miR-191-5p, and miR-423-5p) were selected from qRT-PCR blood studies (21, 22) and from suggested miRNA endogenous controls in the TaqMan Advanced miRNA Assays white paper (Applied Biosystem, Thermo Fisher Scientific). The candidate reference genes were tested for stable expression across sRNA-Seq data results with the following criteria: (a) high read count in all samples; (b) no intra-and intergroup DE (P-value < 0.05). miR-103a-3p and miR-191-5p were found to fit these criteria, so they were selected as internal references.
In the comparison between subjects with PedMS and PC, 13 miRNAs (let-7a-5p, let-7b-5p, miR-25-3p, miR-125a-5p, miR-942-5p, miR-221-3p, miR-652-3p, miR-182-5p, miR-185-5p, miR181a-5p, miR-320a, miR-99b-5p, and miR-148b-3p) were confirmed significantly DE (P < 0.05) (with only the last miRNA downregulated and the others upregulated, as in the sRNA-seq analysis) (Fig. 2 and Supplementary Material).
Gene target prediction
Among the DE genes, we searched for targets of the overall 27 mature miRNAs resulted from the PedMS vs. PC comparison (the total numbers of genes are indicated in Table 2 ). Following both the approaches detailed in the methodological section, for the 13 validated miRNAs that resulted from the comparison PedMS versus PC, we found that 68 significantly down-regulated target genes resulted experimentally validated or computationally predicted (Table 2) . Interestingly, E2F2, DIP2A, GID4, GOLGA8A, KLHL14, CDC34, RPL35A, MICAL3, and DNAJA4 were shared by at least two of the following miRNAs: let-7a-5p, let7b-5p, miR-181a-5p, miR-320a, miR-25-3p, miR-185-5p, and miR-125a-5p (Fig. 3A) . Table 2 also shows the total numbers of target genes that were significantly DE in our integrated analysis, including those upregulated; as already reported, no complete overlap between the overall target genes and their validated miRNA expressions was found in our combined data (23) (Supplementary Material for details).
Pathway analysis
Cluster analysis of the 13 validated miRNAs identified several common KEGG pathways, the most significant being those implicated in Prion disease (hsa05020), fatty acid biosynthesis (hsa00061), cell cycles (hsa04110), Hippo signaling pathway (hsa04390) and adherence junction processes (hsa04520) (P < 0.00001; Fig. 4A ). Together with their target mRNAs that were significantly DE in our analysis (926, up-/downregulated), GSEA showed that significant immunological signatures were implicated (Fig. 4B) . The most representative (10/13 miRNAs) was the network of genes downregulated in peripheral blood monocytes (PBMC), which helps to distinguish from infectious from non-infectious causes of inflammatory response (GSE9960), followed by the one identified by genes upregulated in hematopoietic stem cells (HSCs) versus granulo-monocyte progenitors (GSE15330) (further details in Supplementary Material).
In the above-mentioned sub-network composed of 7-miRNAs (let-7a-5p, let-7b-5p, miR-181a-5p, miR-320a, miR-25-3p, miR-185-5p, and miR-125a-5p), molecular mechanisms related to lysosomial activities, such as endocytosis, phagocytosis, and autophagy, were the main features of the most representative canonical pathway (KEGG_lysosome), whereas among the functional categories of biological processes (GO-terms), the most representative network enclosed any response to oxygen molecular compounds. Finally, GSEA significant pathways evoked the involvement of genes implicated in innate immune responses of PBMCs, dendritic cells (DCs) HSCs (Fig. 3B) .
Discussion
As far as we know, this is the first investigation combining original individual miRNAs/mRNAs data of patients with PedMS. The analysis showed that 12 mature miRNAs were significantly upregulated (let-7a-5p, let-7b-5p, miR-25-3p, miR-125a-5p, miR-942-5p, miR-221-3p, miR-652-3p, miR-182-5p, miR-185-5p, miR-181a-5p, miR-320a, and miR-99b-5p) and 1 miRNA was downregulated (miR-148b-3p) in PedMS patients compared with PC subjects. Furthermore, the analysis of the interactions between the DE miRNAs and their DE targets (mRNAs) uncovered several predicted genes, which a subsequent enrichment analysis categorized in functional pathways. Taken together, in Table 2 . List of the significant miRNAs (discovery/validation steps), and the most significant overlapping target genes. The first section (from the left) listed the 27 miRNAs that resulted significantly different (up/down-regulated: second column) in the comparison between PedMS and PCs performed in the discovery phase (NGS); for each miRNA, the main attributes from the sRNA-seq analysis (mean reads, log-Fold change, dispersion index and adjusted P-value) have been detailed. The central section shows the results of the technical validation (log-Fold change, P-value), confirming 13 miRNAs (top 13 in the list). In the last section (on the right), for each miRNA we summarized the total numbers of target genes that resulted significantly DE in our data, and among them only the overlapping genes reported computationally predicted or experimentally validated as target by published studies In the last column, those genes that targeted more than one miRNA are identified in bold (results outlined only within the 13 confirmed miRNAs, although some of these common genes were also targeted by the non-validated miRNAs; details in Fig. 2 and Supplementary Material).
a Experimentally validated target genes (Luciferase assay).
b miRNAs that have been already reported associated with MS (see Discussion for comments and references).
our view, these results draw a plausible picture of the PedMS molecular signature and suggest in-depth molecular investigations on novel circulating biomarkers and candidate genes.
In the last few years, many published reports addressed the attention to the dysregulation of miRNAs as deeply implicated in the pathogenesis of MS (15, 24) or correlated their circulating expressions, for example, with MRI measures of MS severity (25) , or with responsiveness to specific MS therapies (26, 27) .
In order to improve the accuracy of identifying miRNAs, genes and functional pathways possibly implicated in MS pathogenesis, and to overcome the limitation of small cohort studies performed, for example, in different tissues, recent consensus-based studies analysed and integrated publically available microarray data (GEO dataset) (23, 28) . In particular, this effort produced two regulatory networks: a miRNA network and a gene-based network independent from each other; as an overall take-home-message, they suggested that DE miRNAs may be more informative than DE genes in uncovering molecular pathways of interest in complex diseases like MS (23) . However, as discussed in the same report, the microarray Table S1 ).
technology allows one to investigate a limited number of miRNAs (900 out of more than 2000), thus limiting the full coverage of these circulating molecular biomarkers.
Microarrays technologies have been gradually replaced by the newly developed high-throughput technologies such as NGS, an innovative approach that provides tremendous potential for profiling both mRNAs and miRNAs. Analysis of a larger set of miRNAs of interest with this technology confirmed the method's feasibility and its potential use in the evaluating miRNAs dysfunctions. However, most of these studies did not investigate other transcription products, such as the correspondent target genes: in fact, each miRNA can regulate hundreds of target genes, so the possibility to neglect the overall impact on the genome functional activities is consistent. Furthermore, post-processing analysis of such large amount of data (several million reads per sample) requires specialized bioinformatics abilities thorough biostatistics knowledge in order to obtain accurate, congruent, and reproducible results. interactions were visualized as a network using Cytoscape 3.5.1. The node intensity color is proportional to fold change between PedMS and PC (red: down-regulated, green: up-regulated). The node size is proportional to the P-value in the differential expression analysis. (B) The table indicates the significant results (P < 0.01) of the pathways analysis (KEGG, GEO, GSEA datasets) within the 7 miRNAs-loop; all pathways resulted up-regulated.
Since our strategy relied on the more extensive NGS approach for both miRNAs and mRNAs, this extended the analysis to additional molecular players, possibly exploring novel pathogenic hypothesis. In fact, the originality and strength of this investigation are the availability of combined miRNAs/ mRNAs data from the same subjects obtained at the same time point, uncovering functional combinations that may be linked to PedMS. The search for target genes and the enrichment pathway analysis identified more complex molecular networks that pointed mainly to the immunological signatures, as expected, and to several other biological processes. It is also worthy to note that, despite the relatively small number of Table S3. recruited subjects, both miRNAs and mRNA expressions were able to accurately predict the phenotypes (PedMS and PC), as indicated by ACC values of 92% and 91%, respectively.
According to published reports, we confirmed the upregulation of miR-181a-5p, miR-320a, miR-25-3p, miR-221-3p, let-7a-5p, let-7b-5p, and miR-125a-5p in experimental allergic encephalomyelitis (EAE) or MS, their longitudinal changes often related to long-term immunomodulant/immunosuppressive treatments (18, 19, 23, 24, 29, 30) . Among their potential targets, significant changes in HLA-DRB5 expression, one of the most confirmed MS genes (31), were combined with the dysregulation of let-7b-5p, miR-320a, and miR-221-3p, reinforcing their possible involvement in the MS pathological network. It is worthy to note that, as for several other target genes, the 3 mentioned miRNAs and HLA-DRB5 have been found significantly upregulated in our analysis. As others have stated (23), we consider that this incomplete overlap between miRNAs and their target mRNAs may be the expression of a more complex network in which the posttranscriptional regulation of the first players impacts the modulations of the others at different degrees (e.g. without fully degrading their target mRNAs, or acting by combining the effect of several genes with opposite functions), thus explaining once more the difficulty to shed light on the genetic background of MS.
In our study, the technical validation failed to confirm the reported association between miR-21-5p, miR-140-3p, miR-144-5p and MS (33) (34) (35) . On the contrary, the analysis showed that miR-185-5p, miR-182-5p, miR-99b-5p, miR-652a-3p, miR-942-5p, and miR-148b-3p were significantly dysregulated in subjects with PedMS and might be potential novel biomarkers of the disease at least in the early ages, if confirmed in larger populations. Although none of these miRNAs have been previously reported in MS association studies, miR-185-5p significantly downregulated the expression of genes known in MS (BACH2) or NMO (FCRL3), whereas the only downregulated miRNA (miR-148b-3p) led to a significantly increased expression of TMED7, a gene involved in the type-1 IFN signaling pathway TLR4-related (32) , and KLF4, a retroviral transduction factor inducing experimental (iPS) neuronal differentiation in MS (36) . Furthermore, miR-652-3p and miR-942-5p, together with miR-320a and miR-221-3p, were significantly involved in the down-regulation of immunoglobulins diversification and recombination (GO accession), as in the p38-MK2 pathway (KEGG nomenclature) already reported to contribute to the oxidative stress that has been observed during the inflammatory demyelination of EAE (37) (details in Supplementary Material).
Looking at our data, it is possible to highlight several other miRNA-mRNA combinations that may be worthy of discussion, like the '7-miRNAs loop' (Fig. 3A) . In our analysis, these miRNAs shared 9 significant downregulated genes that were experimentally validated (by the Luciferase assay) or computationally confirmed as targets by at least 2 datasets, and were associated with significant expression changes of 592 other genes (up-/ downregulated). Besides confirming the association between let-7a-5p, let-7b-5p, and MS (35), our combined analysis uncovered a possible functional connection between these 2 miRNAs and miR-125a-5p, via the DIP2A gene, whose expression was found to be related to the burden of another neurodegenerative disease like AD (38) , and to miR-185a-5p via MICAL3, a flavoprotein involved in the cytokine regulation process (39) . In the same network, we pointed to the novel association between miR-181a-5p and MS (miR-181 has been mentioned in EAE) via DNAJA4, a gene that belongs to the cholesterol biosynthesis pathways (40) .
However, since we investigated the recruiting pathways using all gene-level data, we were able to reveal even weak but biologically relevant expression changes of genes, therefore enlightening small but coordinate changes that contribute to the functional networks at different levels. On this basis, we first confirmed that the final 13 validated miRNAs, together with their significant suggested targets (674 mRNAs, up-/downregulated), were implicated in several immunological pathways related to the innate responses of PBMCs, HSCs and DCs, as well as to the adaptive immunity of CD8þ and B-cells (Figs 3B and  4B) . Interestingly, miR-320a, let-7a-5p, let-7b-5p, miR-185-5p, and miR-125a-5p and their target genes contributed to upregulate the network involved in the early activation of immune cells (lymphocytes T-B included) to viral infections, partly driven by innate cytokines and IFN type-1. Members of the TNF superfamily (e.g. TNFSF13B) and the TLR2 gene were among those enclosed in these functional pathways (41, 42) , together with the GRN gene (targeted by let-7b-5p, miR-125-5p, and miR320a), confirming once more their involvement in MS pathogenesis (43); all these genes were significantly DE in our analysis (adjusted P-value < 0.05, see Supplementary Material).
On the other hand, we also noted that 'less predicted' pathways or functional categories emerged from the analysis, hence drawing the attention to several of their gene members as promising candidate genes involved in MS susceptibility. Among the others, the KEGG lysosomal cycle was one of the most significantly involved in 5 out of the 7 outlined miRNAs ( Fig. 3B and Supplementary Material). In line with recent studies establishing that functional SNPs in key genes of autophagy, like ATG7 and ATG16L1, may be potentially responsible for the subsequent impact on adaptive immune cells' long-term survival (44,45), we found these two genes significantly dysregulated in PedMS compared with PC. Notably, ATG16L1 was also reported to be implicated (although decreased) in the EAE pathogenesis together with LAMP2 (46), the latter being one of the most frequently targeted by our validated miRNAs (7/13) and a member of the previously mentioned immunological GSE9960 network that was found to be significantly represented in our study. Furthermore, in the same pathway we discovered that SORT1, a recently evaluated -although controversialplayer in the immune processes of autoimmune inflammation (47) was significantly upregulated in PedMS versus PC, targeted by miR-125-5p, miR-181a-5p and miR-185-5p.
Similarly, target genes related to the ATPase activator activity, ATPase binding and ATPase regulator activity, were found to be significantly implicated: ABCA1 (ATP binding cassette subfamily A member 1), targeted by miR-25-3p and reported to be associated with MS (48, 49) ; and GPX3 (target of miR-185-5p), functionally implicated in ALS neurodegeneration (50, 51) . Figure 5A (interactive at: http://www.ba.itb.cnr.it/pedms/) summarizes the most frequently implicated genes in our analysis, some of them already reported associated with MS, like ZBTB16, AHR, BACH2, CD72 and LAMP2 (details in Fig. 5B) . Genes already mentioned in the previous paragraphs seem crucial, both as targets of several miRNAs of interest and intersectional nodes of functional metabolic network. In vivo functional validations of the most promising targets are in progress, in order to narrow the investigations to fewer candidate genes; subsequent step will include the search for SNPs that may justify the gene expression changes, possibly confirmed in larger MS populations.
This study suffers for some recruitment biases that unfortunately we could not avoid due to limitations imposed by our regional Ethical Committee. As indicated in the opportune section, PC subjects were significantly younger than those with PedMS: considering the age ranges of our study population, we did not obtain permission to recruit healthy subjects, for example, among PedMS patients' schoolmates, but we had the permission (and parents' consent) to use the blood samples of children who were routinely screened (and tested negative) for inflammatory and hematological diseases at the Hematology Day-Care of the Pediatric Hospital in Bari. Only few of them matched the same age, but we decided to include them anyway, also according to published evidences on age-related molecular signatures in healthy as in pathological conditions, establishing a temporal interval not far from our study range (52, 53) .
Another possible objection might be represented by the relatively small sample size and the lack of a replication study in an geted genes, together with their miRNAs (significantly DE between PedMS versus PC, P < 0.05) and the most significant pathways in which they were involved (GSEA database). For each gene, the numbers of miRNAs occurrences and pathways interceptions are visualized in the graph by the ring size (the higher number, the bigger ring) and detailed in (B). For each gene, we summarized the most interesting functional meaning and association with neurological diseases, if any. independent sample, mostly due to the rarity of PedMS occurrence; however, in our view this flaw should not limit the validity of the results considering their prediction accuracy (over 90%).
In conclusion, in our view this extensive analysis enabled us to identify possible molecular signatures of PedMS, confirming the need of such an integrated approach for shedding light on complex diseases like MS. Pathways related to immunological functions were confirmed to be implicated, as well as genes involved in autophagy and ATPase activity, thus suggesting further molecular investigations that may expand the pathogenic hypothesis of MS (Supplementary Material). No significant molecular features were found to be associated with measures of clinical disability or cognitive deterioration. However, a longitudinal 1-year observation of the same subjects is in progress, looking for peculiar molecular profiles of clinical and MRI changes, and responses to DMT. During the developmental ages like in PedMS, this may carry the promising chance to intervene with targeted therapeutic approaches in order to prevent irreversible disabilities.
On the other hand, a validation study on an adult MS group is in progress, in order to verify whether the reported molecular profile is a peculiar signature of PedMS rather than a common feature of the disease independently from age.
Subjects and Methods

Study populations
The investigation was performed on samples belonging to Caucasian patients with childhood and juvenile MS (4,54,55) recruited within 5 years from the onset and followed up at the Department of Basic Sciences, Neurosciences and Sense Organs, University of Bari, by neurologists and neuropsychologists with a primary interest in MS. The start date of recruitment was September 2015. At study entry, patients' demographic and clinical features were collected: age, disease course and duration, and Expanded Disability Status Score (EDSS) (56) . A validated neuropsychiatric (NPS) test battery, exploring several cognitive domains, was administered to patients with PedMS by a trained neuropsychologist (test duration: 45-min to 2 h). According to published guidelines, cognitive impairment was conferred after a failure of at least three tests (57) .
PCs were selected among the young subjects routinely admitted at the Hematology Day-Care of the Giovanni XXIII Pediatric Hospital of Bari who tested negative for any inflammatory and hematologic diseases.
The study was approved by the Ethics Committee of Azienda Ospedaliera Policlinico, University of Bari. Since the study subjects were all under the age of 18 years, their legal tutors signed written informed consent forms (according to the Declaration of Helsinki) at the time of the enrollment.
Molecular analysis of peripheral blood samples
Sample preparation Peripheral blood samples were taken from patients and controls and stored at À20 C in 3ml PAXgene Blood RNA Tubes (PreAnalytiX Qiagen/BD, Hombrechtikon, Switzerland). Total RNA was isolated using the PAXgene Blood RNA Kit (PreAnalytiX Qiagen/BD, Hilden, Germany) at ITB CNR, Bari. RNA concentration and purity were measured by Nanodrop ND-1000 (Thermo Scientific, Wilmington, DE, USA) and RNA 6000 Pico chip on Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA), respectively. Samples with RNA Integrity Number (RIN) scores higher than 7 and with A260/A280 values in the 1.8-2.2 range were processed in downstream deep sequencing.
High-throughput next-generation sequencing (HT-NGS)
RNA samples were sequenced using an Illumina HiSeq2500 platform service (http://www.genomix4life.com/en/). Small RNA (sRNA) libraries were prepared using the TruSeq Small RNA Sample Preparation kit (Illumina, San Diego, CA, USA) following the manufacturer's instructions. Briefly, 1 mg of total RNA was ligated with 3 0 and 5 0 adapters, reverse transcribed, and amplified by 15 cycles of PCR using a unique index for each reaction. PCR products of 140-160bp were isolated following electrophoresis through a 6% Novex Tris-borate polyacrylamide gel, precipitated with ethanol, and fluorimetrically quantified. The quality of libraries was confirmed using a High Sensitivity DNA Analysis Kit on a Bioanalyzer 2100 instrument (Agilent Technologies, Santa Clara, CA, USA). A multiplexed pool consisting of equimolar amounts of individual sRNA-derived libraries was sequenced to generate 50-bp single-end reads, resulting in a final output of around 10 million reads per sample. The mRNA libraries were prepared using the TruSeq Stranded mRNA Sample Preparation kit (Illumina, San Diego, CA, USA). Briefly, 1 mg of total RNA was used for poly-A mRNA selection with oligo-dT beads, followed by thermal mRNA fragmentation and reverse transcription (RT). The complementary DNAs (cDNAs) were 3 0 -end adenylated and ligated to Illumina Paired-end sequencing adapters and subsequently amplified by 12 cycles of PCR. The libraries were fluorimetrically quantified and analysed on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), pooled equimolar into a multiplex sequencing pool and sequenced to generate 2x100bp paired-end reads, leading to a final output of around 30 million reads per sample.
RT and microfluidic qPCR
Approximately 8ng of total RNA/sample was reverse transcribed into cDNA using the TaqMan Advanced miRNA cDNA synthesis kit (Applied Biosystems, Thermo Fisher Scientific). The ends of each mature miRNAs were extended with 5'-end ligation of an adaptor sequence and 3' poly-A tailing, and recognized by universal RT primers (Applied Biosystems, Thermo Fisher Scientific). The obtained cDNA was amplified using the Universal miR-Amp Primers (Applied Biosystems, Thermo Fisher Scientific), diluted, and served as a template for microfluidic qPCR analysis with TaqMan Advanced miRNA Cards (Applied Biosystems, Thermo Fisher Scientific). The TaqMan microfluidic card is a customdesigned miRNA assay, preconfigured in a 384-well format and spotted onto a microfluidic card. The card contains eight sampleloading ports, each connected by a micro channel to 48 miniature reaction chambers, enabling the simultaneous quantitation of 42 human miRNAs plus 5 candidate endogenous reference genes for a total of 4 samples per card (2 replicates per assay). Briefly, 25 ll of diluted pre-amplified product was mixed with 50 ll of TaqMan
Fast Advanced Master Mix (Applied Biosystems, Thermo Fisher Scientific) and 25 ll of nuclease-free water; 100 ll of the PCR reaction mix was dispensed into each port of the TaqMan Advanced miRNA Card. Each card was centrifuged, sealed with a TaqMan low-density array sealer (Applied Biosystems, Life Technologies) and placed in the microfluidic card sample block of an ABI Prism V R 7900HT sequence detection system (Applied Biosystems, Life Technologies). Finally, PCR amplification was performed. Thermal cycling parameters were 10min at 92 C to enzyme activation, 40 cycles of denaturation at 95 C for 1sec, and annealing and extension at 60 C for 20 sec.
Raw Ct values were calculated using RQ manager software v.2.3 (ABI). (Fig. 1 ).
Statistical analysis
Two normalization tools, NormFinder (58) In particular, genes were filtered out if they failed to achieve a count per million (cpm) value of 1 in at least 20% of samples. The expressions were simultaneously scale normalized using TMM and variance was stabilized using the voom technique; the corresponding log-cpm values and associated weights were input to the limma standard linear modeling and empirical Bayes for DE analysis. An adjusted P-value <0.05 was considered significant for evaluating changes of the expression. g. Global differences between phenotypes: Differences at the global level between different phenotypes by using molecular data were assessed through two methods: Principal Component Analysis (PCA) and Support Vector Machines (SVM). An unbiased estimation of the Prediction Accuracy was assessed using the Leave-One-Out Error (LOOE) procedure (62, 63) . The percentage of correctly classified samples is an unbiased estimate of the prediction accuracy. In our context, the higher the prediction accuracy, the greater the difference at a molecular level between the two different phenotypes analysed. When we estimated the prediction accuracy using an unbalanced data set, we randomly drew from the largest data set a number of samples equal to the smallest data set and measured the LOOE error on this reduced sample. We repeated this procedure 100 times and evaluated the mean LOOE (Fig. 1 , see Supplementary Material for additional references).
MicroRNA target analysis
Starting from the results of the DE analysis performed on the two types of datasets (sRNAs and mRNAs), the relationships among differentially expressed miRNAs and differentially expressed target genes were investigated through a bioinformatics approach. The interactions among miRNAs and their target genes were selected using two databases of experimentally validated bindings (miRtarbase: http://mirtarbase.mbc.nctu.edu.tw; DIANATarbase: http://diana.imis.athena-innovation.gr/Diana Tools/index.php? r¼site/index), and the output of 5 algorithms for target predictions: miRanda (http://www.micro rna.org/microrna/home.do), RNAhybrid (https://bibiserv. cebitec.uni-bielefeld.de/rnahybrid), rna22 (https://cm.jeffer son.edu/rna22), mirDB (http://ophid.utoronto.ca/mirDIP), and TargetScan (http://www.targetscan.org/vert_71). The algorithms were run on 3'-UTR sequences from RefSeq human transcripts, with default parameters, except for miRanda (score: 150, energy: 7) and RNAhybrid (P-value: 0.1, energy: À22), as suggested in the literature (Supplementary Material, Ref-S15).
To address the low precision and poor sensitivity of the computed target predictions (Supplementary Material, Ref-S16 and S17) and to strengthen the results of interaction identification, we finally selected those bindings that were confirmed by the Luciferase assay in the previously mentioned databases or computationally predicted at least by 2 algorithms (seeds region at the same position reported in at least 2 datasets) (also for this section, see Supplementary Material for additional references).
Pathway analysis
To first unveil common functional pathways, if any, among the validated miRNAs, the web-based computational DIANAmirPath software was used (64).
In order to determine the role of deregulated miRNAs and target genes in PedMS, we then performed a pathway analysis with a computational method that integrates HT-NGS expression data with miRNA target predictions (65) . We considered the association between miRNAs and their target genes together with a collection of sets of genes, associated with particular biological processes (such as Gene Ontology categories), canonical pathways or experimental results. The hypothesis was that if the genes annotated with some biological processes that are targets of a specific miRNA differentially expressed, it was reasonable to infer that this miRNA was involved in the dysregulation of this process.
In detail, for each specific miRNA, the method considered the intersection among gene sets and miRNA-targets associations. An enrichment pathway analysis was performed on these gene sets to identify the biological processes in which these genes -which are also miRNA targets -resulted in up-or downregulation.
To this aim, an enrichment analysis based on the Gene Set Enrichment Analysis (GSEA) algorithm with unweighted enrichment scores (exponent P ¼ 0), which distinguishes up-and down-regulated pathways, was adopted. GSEA is a computational method that allows one to retrieve gene sets that are enriched at either the top or the bottom of differentially expressed genes ranked by some measure of differences in gene expression across sample classes (http://software.broadinsti tute.org/gsea/index.jsp). An unpaired t-test measures the gene DE in GSEA. GSEA adopts a threshold-free approach and uses the expression data of all the detected genes, thereby reducing the chance of missing weak but biologically relevant expression changes. The method can detect small but coordinated changes of genes that collectively contribute to some biological process.
Supplementary Material
Supplementary Material is available at HMG online.
